Santé log

Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026

The Phase 3 ECLIPSE clinical trial evaluates lutetium-177 (Lu-177) zadavotide guraxetan (a proprietary formulation of 177 Lu-PSMA-I&T), an investigational prostate-specific membrane antigen ...
Santé log

Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA

Fagron, the leading global player in pharmaceutical compounding, announces that it has completed the acquisition of Pharmavit Europe, a leading European distributor of nutraceutical raw materials ...
Santé log

OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer

NANTES, France, February 26, 2026 – 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced that the Independent Data Monitoring Committee (IDMC) has issued a second ...
Santé log

BeautyHealth to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced it will report fourth quarter and full year 2025 financial results after market close on Thursday, March ...
Santé log

AMN Healthcare Survey Reveals Sharp Divide Between Leaders’ Organizational Confidence and Industry Outlook for 2026

Survey of 700+ executives shows AI leadership roles surging as succession planning and clinician engagement lag DALLAS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- While nearly three-quarters of healthcare ...